SEXUALLY TRANSMITTED diseases 1J (STDs) have been a public health concern over the centuries. Today STDs are a public health problem with over twenty recognized pathogens. New syndromes, such as acquired immune deficiency syndrome (AIDS) and bacterial vaginosis, have also been established during the past 10 years. The purpose of this article is to review the epidemiology, clinical presentation, diagnosis, and treatment of commonly occurring STDs. HIV has added to the complexity of STDs and has altered some of the therapeutic regimens. Recommendations for prevention and management will not be addressed in this review.
GONORRHEA Neisseria gonorrhea is one of the oldest known and most widely recognized STDS. Many patients (women more commonly than men) are asymptomatic or present with nonspecific findings that increases the spread of disease. Transmission is primarily through sexual contact.
Perinatal transmission may also occur. The highest rates of gonorrhea occur in the 20to 24- year-old age group.' Clinical Presentation ~ &dquo;
The primary symptomatic manifestation of gonococcal disease in males is urethritis, including a profuse and purulent urethral discharge and dysuria. Frequency and urgency are not usually observed. Infected males may often remain asymptomatic.
The primary site of infection in females is the endocervix. Manifestations of uncomplicated genital infections include cervicitis, urethritis, or both. Any one or more of the following symptoms may develop: increased vaginal discharge, intermenstrual bleeding, lower abdominal pain, menorrhagia, and dysuria. More serious complications from invasive disease are meningitis, ophthalmia, and disseminated gonococcal infection (DGI). Ascending genital tract infections can cause acute salpingitis in females and acute epididymitis in males.
Diagnosis
Diagnosis is usually made by culture of the organism. In all males, the urethra should be cultured. In females, both endocervical and rectal specimens should be cultured; this has been found to significantly increase the yield of diagnosis.' Pharyngeal cultures should be taken if orogenital exposure has occurred. A gram stain of the discharge will show gram-negative diplococci with neutrophils. In most cases, a gram stain alone is insufhcient for making a diagnosis.
If cultures are unobtainable, other diagnostic tests are available. The new diagnostic aids include enzyme immunoassays, tests for detection of monoclonal .antibody, and tests that identify gonococcal DNA or endotoxin. However, none of these tests should replace the use of cultures for diagnosis at the present time.
Treatment
Penicillinase-producing Ngorlorrhea (PPNG) strains have rapidly increased during the 1980s.
In 1988, greater than 4% of cases were penicillinresistant.' In some US cities, eg, New York and Detroit, prevalence of PPNG is greater than 20%. Tetracycline-resistant strains have also been identified, accounting for a smaller percentage of resistant cases.4 Therefore, penicillin is no longer recommended for initial therapy. Ceftriaxone is presently the drug of choice for gonococcal infections (Table 1 ). In the treatment of ophthalmia in adults, a single 1-g injection of ceftriaxone has been found effective ; however, further treatment is necessary when septicemia is present.
Ceftriaxone has been found as effective at the lower dose of 125 mg, intramuscularly administered as a one-time dose.s-' Wide acceptance has been slow due to concern over the possible Reprinted with permission.' emergence of ceftriaxone-resistant strains when using lower doses; however, no organism resistant to ceftriaxone or any other third-generation cephalosporin has been noted to date.'
Recommendations also include the simultaneous administration of doxycycline (or erythromycin in pregnant women) for the treatment of Chlamydia trachomatis when treating N gonorrltea.
The current recommendation for patients who cannot take ceftriaxone is spectinomycin. Dosage regimens of spectinomycin along with other alternatives are listed in Table 2 . Ciprofloxacin, norfloxacin, and ofloxacin may become the treatment of choice due to its ease of administration and low cost. Fluoroquinolones are not recommended for children age 16 or less and therefore should be avoided in pregnant women.
For the treatment of disseminated gonococcal infection, ceftriaxone (1 g intramuscularly [IM] or intravenously [IV] daily), ceftizoxime (1 I g IV every 8 hours) or cefotaxime (1 g IV every 8 Reprinted with permission,' hours) may be used as initial therapy.8.9 If the organism is penicillin sensitive, the antibiotic should be switched to a penicillin regimen (penicillin 10 million units per day). Once the patient has defervesced, they may be switched to oral therapy (cefuroxime axetil 500 mg twice daily or amoxicillin 500 mg with clavulanic acid 3 times daily to complete 1 full week of treatment).8 CHLAMYDIA C trachoiiiatis is currently the most common sexually transmitted bacterial infection in the United States. It is also the most frequently isolated pathogen in both nongonococcal urethritis (NGU) and postgonorrheal urethritis (PGU). Similar to other STDs the risk factors include young age, single, low socioeconomic status, urban residence, and multiple sexual partners. It has been postulated that chlamydial infections are less contagious than gonococcal infections due to the lower recovery rate of C trachomatis from sexual partners of culturepositive patients.'&dquo;&dquo; This data may be misleading due to the difficulty in specimen collection and culturing techniques.
C tracfiornatis is an obligate intracellular bacteria that appears in two forms, the elementary body (EB) and the reticulated body (RB). The EB is the inactive transport form that will undergo phagocytosis by the host cuboidal cells.
Once within the host cell, the EB will change into the metabolically active RB. The RBs will replicate and then reorganize into the transport form. The host cell membrane will lyse, thus releasing EBs to repeat the cycle, which takes 48 to 72 hours.
Currently, 15 different serovars of C trachottiatis have been isolated. Types A, B, Ba, and C are the causative agents of endemic trachoma and types Ll, L2, and L3 cause lymphogranuloma venereum. Serotypes D through K are associated with infections of the upper and lower genital tracts, the lower gastrointestinal tract, conjunctivae, and perinatal infections.
Clinical Presentation
Uncomplicated genital C traclromatis infections are superficial, indolent, and often asymptomatic. The signs and symptoms are very similar to those of gonococcal infections making accurate diagnosis difficult. Symptoms are usually less pronounced than with gonococcal disease and the incubation period is longerbetween 7 and 21 days.
In males the most common site of infection is the urethra. Males with NGU may present with urethral discharge, itching, frequency, dysuria, meatal erythema, or tenderness.&dquo; Between 40% and 80% of patients exhibit none to mild transient symptoms. Proctitis in homosexual males presents with rectal discharge, anorectal pain, and tenesmus. When the infection is due to serovars Ll-L3 there is increased severity in the symptoms. In men younger than 35 years, C tracfioniatis is the leading cause of epididymitis. '3 Overall, less than 2% of patients with NGU develop epididymitis. Thus far, chlamydial infections have not caused male infertility.&dquo;
In women the most common site of infection is the cervix. The majority of females are asymptomatic. On examination, cervicitis with a mucopurulent discharge or a friable appearance may be observed. Symptoms may include discharge, intermenstrual bleeding, and dysuria.
Less common sites of infection include the urethra and vestibular glands. Because of the indolent nature of the organism, patients may have a long standing infection.&dquo; Over 10% of females with chlamydial infections will develop salpingitis or pelvic inflammatory disease (PID). Chronic pain syndrome and involuntary infertility is associated with C trachoma/is upper geni-. tal tract infection.
Diagnosis .
Laboratory evaluation is necessary for the diagnosis of C traclromatis infections.12 Direct microscopic examination of the cell scrapings from the urethra or cervix should be performed to rule out gonococcal infection and to assess the presence of neutrophils. Specimens must contain cellular matter.
Currently, three laboratory methods are available. Direct culture of the EB may be done using cell (HeLa or McCoy) cultures. This method is the most specific but is expensive, labor intensive, with a slow turnaround time.
Accurate results depend on living EBs. New rapid methods use monoclonal antibodies to the outer proteins on the EBs. These tests can detect living or nonliving EBs. Either fluores-cein-conjugated monoclonal antibodies or enzyme-linked immunosorbent assay (ELISA) allow diagnosis within a few hours. If a test of cure is performed using the rapid antigen detection kits, the sample should be obtained 1 month following the completion of therapy to prevent false-positive results due to nonliving material.
Treatment
Because of the high prevalence rate of coexisting infection with gonococcus and chlamydia, presumptive therapy for both organisms should be initiated for all patients.&dquo; Tetracyclines are highly effective in treating C trachomatis infections and are the agents of choice (Table 1 ). Tetracyclines are also effective against other organisms that may cause NGU (ie, Ureaplasitia llrealyticllm). Doxycycline therapy is preferred over other tetracyclines because it is highly effective with twice daily dosing leading to better compliance, better tolerance, and no food interaction. Minocycline is not recommended due to cost and toxicity. Because of tetracyclines' adverse effect on tooth enamel and bone growth, erythromycin (not estolate) is the drug of choice in children and pregnant women.
Erythromycin is the alternative agent of choice for adults unable to tolerate tetracyclines. Alternative treatment guidelines are provided in Other conditions that cause pelvic pain (ectopic pregnancy, endometriosis, appendicitis) make accurate diagnosis difficult. When C trachoniatis is the primary infecting organism, the clinical presentation may be less acute due to milder disease and subclinical infection. This form of PID may be more difficult to detect and to treat.
In the past, diagnosis of PID was based on clinical presentation and laboratory findings that were accurate in only 65% of the cases 2' Today, laparoscopy is the gold standard for the diagnosis of pelvic inflammatory disease.' Ultrasound examination is also helpful for the diagnosis of PID, especially for the identification of tuboovarian abscess.
Because PID is a polymicrobial disease, broadspectrum antibiotic coverage is necessary. Several antibiotic regimens for inpatient and outpatient therapy are provided in Table 4 .~ No one regimen is clearly superior to the other, each having their advantages and disadvantages.
The efficacy of combination [3-lactams and doxycycline has been well documented. This combination will provide excellent coverage against chlamydia, gonorrhea, and gram-negative pathogens. It is less effective against anaer- fieprinted with permission.&dquo; obes than other regimens. Accepted (3-lactam antibiotics include cefoxitin, cefotetan, ceftriaxone, ceftizoxime, and cefotaximc.19 Cefotetan may be preferred over cefoxitin because of its longer dosing interval. Doxycycline is equally efficacious when administered orally or intravenously. Therefore, unless otherwise contraindicated, the patient should receive oral therapy.
Another accepted regimen for PID is an aminoglycoside with clindamycin (metronidazole may not be substituted alone for lack of facultative anaerobic coverage). This combination provides excellent activity against anaerobes, gram-positive and -negative bacteria, and excellent penetration of tuboovarian complexes. Unlike other abscesses, tuboovarian abscess will resolve following appropriate antibiotic therapy. High-dose clindamycin has some antichlamydial activity with recent investigations supporting its efficacy.24
Inpatient management is recommended for all patients with severe PID, for an uncertain diagnosis (especially when surgical intervention may be necessary), when tuboovarian abscess is suspected, for poorly compliant patients (especially adolescents), and patients that cannot be followed-up in 72 hours.
All hospitalized patients are to be treated with intravenous antibiotics until 48 to 72 hours following clinical improvement. Patients should be discharged on doxycycline 100 mg by mouth twice daily to complete a 14-day course. If doxycycline cannot be tolerated, clindamycin 450 mg 5 times daily for 14 days may be substituted.'
..
-Outpatient management of PID is provided in Table 4 . Secondor third-generation cephalosporins given as a single dose with doxycycline is the preferred regimen. Due to the increased frequency of penicillinase-producing N gonorrhoea, penicillins are no longer recommended. Patients should be followed closely and if no improvement occurs within 72 hours, hospitalization should be considered. SYPHILIS Syphilis has long been a major health concern in the United States. Between 1945 and 1985 the number of reported cases has been on the decline. Since 1985, a resurgence of reported cases of syphilis has occurred. Syphilis is caused by Trepoizettiapallidtitti, a member of the Spiro-chaetaceae family. Due to the serious complications of untreated syphilis, it is extremely important to diagnose and treat the patient and sexual contacts.
Clinical Presentation
Syphilis is primarily acquired through sexual intercourse. Other routes of transmission include kissing, transfusions, and transplacental passage. It is divided into primary, secondary, early latent, and late latent stages. Clinical presentation and treatment varies depending on the stage of syphilis at diagnosis. The development of chancres at the site of inoculation refers to primary syphilis. More than one lesion may develop. Usually these chancres have no exudate and are painless (unless secondarily infected). The lesions generally heal within 3 to However, in the treatment recommendations by the Centers for Disease Control (CDC), early latent syphilis is considered to have an infection period of less than 1 year 2' Late latent syphilis is when patients develop tertiary manifestations such as neurosyphilis, cardiovascular or gummatous (granulomatouslike) syphilis. Any part of the body may be involved at this stage. Although neurological involvement may occur at any stage of the illness, neurosyphilis refers to a tertiary manifestation where meningovascular and parenchymous signs are noted. Headache and a stiff neck occur frequently with CNS involvement. However, patients can be asymptomatic. The cerebral spinal fluid (CSF) may show elevated protein levels, lymphocyte count, or the presence of spirochetes. It should be noted that patients may be asymptomatic with no CSF changes and still have neurosyphilis.
Diagnosis
Syphilis is a difficult diagnosis to make. It has been labeled the &dquo;great imposter&dquo; because it mimics so many other diseases. Once syphilis is diagnosed, treatment should begin immediately. T pallidum is not easily cultured and diagnosis must be made through other tests. 28, 29 Nontreponemal tests refer to the two following tests: Venereal Disease Research Laboratory (VDRL) or rapid plasma reagin (RPR). These are quantitative measures reported out as titers. VDRL is the test most commonly followed to assess therapeutic response. These tests correlate with disease activity (ie, highest titers with secondary syphilis and lowest with latent syphilis).30 Titers usually decrease fourfold by 3 months of treatment and eightfold after 6 months of treatment.
Treponemal tests are used to confirm positive results of nontreponemal tests. Fluorescent treponemal antibody-absorption (FTA-abs) is sensitive and specific. This is the first test to become positive during early syphilis and usually remains positive despite effective treatment. ' Other treponemal tests include T pallidu11l hemagglutination assay (TPHA) and microhemagglutination assay for antibody to T pallidu11l (MHA-TP). All of the treponemal tests are reported as reactive or nonreactive rather than as titers. Unlike the nontreponemal tests, these do not correlate with disease activity.
Darkfield examination looks at the serous transudate from a primary lesion or mucous patch to identify T pallidum. It can be falsely negative if the patient has had recent antibiotic therapy or used topical antiseptics.29 The lesion is considered negative once three examinations have been performed. It is recommended that mouth lesions be avoided because false-positive results may occur.
Diagnosis of neurosyphilis is based on neurological findings, CSF changes, and serologic testing. A reactive CSF-VDRL is considered diagnostic; however, a negative test cannot rule out neurosyphilis. CSF-FTA-abs has not been found to be a reliable test.25 Neurological involvement can be asymptomatic making diagnosis difficult.
Treatment
Penicillin is the agent of choice. Alternatives for the penicillin-allergic patient include doxycycline or tetracycline. Dosage recommendations and treatment duration for each disease stage may be found in Table 5 .&dquo; When the disease stage is uncertain, the patient should receive the recommended regimen for late latent syphilis. Erythromycin (500 mg by mouth 4 times daily times 2 weeks) has also been recommended as an alternative regimen; however, it should be reserved for penicillin-allergic patients who can- Reprinted with permission.&dquo; not tolerate doxycycline or tetracycline. When using alternative agents, compliance must be stressed. Newer treatment alternatives include ceftriaxone 250 mg IM once daily times 10 days. However, risk of cross-reaction in penicillinallergic patients and high cost makes ceftriax- Penicillin is the only agent recommended for neurosyphilis at this time. Penicillin-allergic patients need to be desensitized prior to treatment. The alternative penicillin regimen listed in Table 1 is to be used only when compliance is assured.
Pregnant women, regardless of gestational stage, must be treated with penicillin.3' Alternative therapy with doxycycline or tetracycline is not an option in pregnant penicillin-allergic patients. Erythromycin is an unreliable agent during pregnancy. Treatment failures in both mother and fetus have been noted -and thus is not recommended.3' Penicillin desensitization must be performed. Penicillin may be used safely once desensitization has been undertaken.
Jarisch-Herxheimer Reactioit . The Jarisch-Herxheimer reaction is a systemic reaction relating to the release of pyrogens from the spirochete. It occurs 1 to 2 hours after initial treatment with penicillin lasting 12 to 24 hours. Common manifestations include fever, headache, and myalgias. In severe cases hypotension may occur. Generally, the reaction can be treated with aspirin. Preadministration of diphenhydramine or corticosteroids does not prevent the reaction. Patients should be monitored for 24 hours, particularly pregnant females because this reaction has been reported to cause uterine contractions and may result in early labor.32 All patients should be warned of this reaction prior to treatment.
GENITAL HERPES
Genital herpes occurs frequently in the United States. Over 31 million people produce antibodies to herpes simplex virus (HSV).33 Herpetic infections are chronic, lifelong, and have no known cure. Herpes is spread through direct contact with the infected area or through infected secretions. HSV has two serotypes. HSV-1 is associated with oral manifestations (cold sores) and HSV-2 causes genital disease. Either serotype can cause infection at the other anatomical site.
HSV infections begin with epithelial involvement with subsequent spread of the virus to sensory nerve ganglia. HSV will remain in the ganglia. There, the virus may remain latent (dormant) or can reactivate, which leads to recurrent infection.
Clirucal Presentation and Diagnosis
Genital herpes infections are divided into two categories: first episode and recurrent. The first episode category is further subdivided into primary and nonprimary infection. Primary first episode infection refers to patients without any HSV antibody production, whereas nonprimary patients produce antibodies to HSV-1. The severity of the infection is greatest with primary first episode and least with recurrent disease.
The incubation period for genital herpes is 6 days (range, 1 to 45 days).' Patients with first episode herpetic infections may present with fever, headache, malaise, myalgias, and local findings of pain, itching dysuria, and discharge. Women Women with BV present with vaginal discharge with or without local complaints. The diagnosis of BV is dependent on the presence of a homogenous noninflammatory discharge, vaginal fluid pH > 4.5, clue cells, and a positive whiff test (fishy odor when KOH is added to vaginal secretion).
Treatment of choice for BV is metronidazole.39 High cure rates are noted following metronidazole 2-g single-dose therapy or with metronidazole 500 mg twice daily for 7 days. Greater relapse rates occur following single dose therapy than extended dose therapy. Alternative therapy for BV is clindamycin 300 mg twice daily for 7 days. Sexual partners, even if they are asymptomatic, should receive 2-g singledose metronidazole therapy.
Trichomoniasis
Trichomoniasis is considered the most prevalent nonviral sexually transmitted disease.&dquo; It is caused by the protozoan Trichomonas vagina/is, a motile pear-shaped extracellular parasite.
Greater than 90% of men and 50% of women with T vagina/is infections are asymptomatic.41
Patients may present with a profuse frothy discharge, itching, and dysuria. T vaginalis infections are weakly associated with serious complications (PID and preterm labor in pregnant women) and leads to bacterial overgrowth or BV in untreated patients. Diagnosis of trichomoniasis is based on the presence of trichomonads in wet-mount examination of vaginal secretion. Cultures for T vaginalis may be obtained, but is not necessary for accurate diagnosis.
Metronidazole is also the agent of choice for trichomoniasis. Initial therapy is metronidazole administered as a 2-g single dose. Patients who fail this therapy will receive metronidazole, 250 mg 3 times daily for 5 to 7 days. Alternative therapy for patients who cannot tolerate metronidazole or who are pregnant is clotrimazole 100 mg intravaginal at bedtime for 7 days. All patients and partners should be treated.
Genital jeans
Genital warts are caused by the human papilloma virus (HPV). Over 50 serotypes of HPV have been isolated. HPV serotypes 16, 18, 31, 33, and 34 are associated with genital infection, dysplasia, carcinoma, and serotypes 6 and 11 with benign lesions 4' Genital warts may be located on the external genitalia, urethra, vagina, perianal, and cervix. The lesions may vary in appearance from small flat plaques to large pigmented (cauliflower) warts. Diagnosis of genital warts is by biopsy. Atypical papanicolaou (Pap) smears and colposcopy examination are also important tests.
Cryotherapy with liquid nitrogen is standard therapy for genital warts.4z Alternative therapy consists of podophyllin, trichloroacetic acid, electrodesiccation, and laser ablation. Interferon is not approved for HPV infections. Cure is eradication of all visible lesions. SUMMARY STDs have reached epidemic proportions in the United States. Not only is there an increased incidence of the older infections such as gonorrhea and syphilis, but also an increase in viral infections such as herpes and genital warts (not to mention AIDS), which have no known cure. Bacterial resistance has also developed to standard regimens. Many patients, especially women, are asymptomatic which hastens the spread of disease. Treatment of the patient is not enough. Every effort should be made to identify and treat all sexual contact.
